Comparative Pharmacology
Head-to-head clinical analysis: GRANISOL versus SANCUSO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRANISOL versus SANCUSO.
GRANISOL vs SANCUSO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Granulocyte colony-stimulating factor (G-CSF) that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
Granisetron is a selective 5-HT3 receptor antagonist. It blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone (CTZ) of the area postrema and on peripheral vagal nerve terminals, thereby inhibiting the vomiting reflex.
375 mg/m2 intravenously over 1 hour every 3 weeks
3.1 mg patch applied to upper outer arm every 24 hours; applied 24-48 hours before chemotherapy and left on for 24 hours after chemotherapy completion.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours) and in the elderly.
Terminal elimination half-life is approximately 25 hours following transdermal application. This long half-life supports the 72-hour dosing interval of the transdermal patch.
Primarily hepatic metabolism with <5% excreted unchanged in urine; biliary/fecal elimination of metabolites accounts for ~60% of total clearance.
Approximately 95% of the dose is metabolized, with <5% excreted unchanged in urine. Metabolites are eliminated primarily via feces (about 70%) and urine (about 25%).
Category C
Category C
5-HT3 Receptor Antagonist
5-HT3 Receptor Antagonist